PTEN and pachyonychia congenita: While this study has utilised PC3 cells, which model metastatic aggressive-variant, castrate-resistant PC with a defined set of genetic alterations including TP53 mutation and PTEN loss [51], extension to other stages of disease progression and mutational profiles is likely to yield further insights that can be exploited in the context of precision oncology.